Abstract P4-01-08: Morphological and functional plasticity of mitochondria in chemoresistant triple negative breast cancer

线粒体 三阴性乳腺癌 癌症研究 乳腺癌 生物 癌症 线粒体分裂 粒体自噬 线粒体DNA 病理 医学 细胞凋亡 自噬 细胞生物学 遗传学 基因
作者
Lily Baek,Junegoo Lee,James P. Barrish,Bora Lim,Jeffrey T. Chang,Phillip L. Lorenzi,Weston W. Porter,Gloria V. Echeverria
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (4_Supplement): P4-08
标识
DOI:10.1158/1538-7445.sabcs21-p4-01-08
摘要

Abstract BACKGROUND: Neoadjuvant chemotherapy (NACT) used for triple negative breast cancer (TNBC) eradicates tumors in only 45% of patients. TNBC patients with substantial residual cancer burden have poor metastasis free and overall survival rates. Therefore, understanding the mechanisms of resistance to standard chemotherapy is essential. Our previous studies found mitochondrial oxidative phosphorylation (OXPHOS) was elevated and was a unique therapeutic dependency of residual tumor cells that survived after NACT. Mitochondria are morphologically plastic and dynamic organelles that continuously cycle between fission and fusion to maintain mitochondrial integrity and metabolic homeostasis. Mitochondrial fusion is thought to support OXPHOS through maintenance of the mitochondrial genome (mtDNA) which encodes 13 subunits of electron transport chain complexes. On the other hand, mitochondrial fission can be the precursor to mitophagy, the selective degradation of damaged mitochondria. We are investigating how mitochondrial structure dynamics impact metabolic states driving chemoresistance in TNBC. Methods We used a previously characterized orthotopic patient-derived xenograft (PDX) mouse model derived from the primary tumor of a treatment-naïve metastatic TNBC patient. After treatment with a standard NACT regimen, combined Adriamycin (aka doxorubicin) and cyclophosphamide (AC), we observed initial partial response followed by tumor regrowth. We collected PDX tumors at three time points: pre-treatment, post-AC residual (when tumors reached the volume nadir), and post-AC tumors that later regrew to the starting tumor volume. We used transmission electron microscopy (TEM) and immunohistochemical (IHC) analysis of human mitochondria to assess mitochondrial morphology and mass, respectively. For in vitro assays, we assessed mitochondria morphology, mtDNA content, and OXPHOS activity in TNBC cells treated with two different types of chemotherapeutic drugs, DNA-damaging agents (doxorubicin and carboplatin) and a microtubule-stabilizing agent (paclitaxel). To examine metabolic adaptations upon chemotherapy, we conducted 13C-glucose and glutamine flux metabolomics. To pharmaceutically perturb mitochondrial morphology, we used Mdivi-1 and Silibinin, known to induce mitochondrial fusion and fission, respectively. We assessed cell growth by Incucyte real-time imaging. Results: Analyses of residual PDX tumors after in vivo AC treatment revealed increased mitochondrial content, and increased average mitochondrial length in residual tumor cells. Metabolomic analysis of TNBC cells revealed all three chemotherapies induced glucose, but not glutamine, flux through the TCA cycle. Flux through glycolysis was not affected by chemotherapies. Treatment with doxorubicin and carboplatin, increased mitochondrial elongation, mtDNA content, and OXPHOS activity. Conversely, paclitaxel treatment reduced mitochondrial length and OXPHOS activity. We observed Mdivi-1 induced fusion concomitant with increased OXPHOS activity, while treatment with Silibinin reduced fusion and decreased OXPHOS. We next tested if induction of mitochondrial fission enhanced chemosensitivity. Sequential treatment of TNBC cells with DNA-damaging chemotherapeutics followed by Silibinin perturbed OXPHOS and resulted in enhanced cell killing. Conclusion: These findings establish a functional role for mitochondrial structure in chemotherapeutic response and metabolic reprogramming, which may confer a survival advantage to TNBC cells. Given the increased chemosensitivity we observed after pharmacologic inhibition of mitochondrial fusion, our study suggests perturbing mitochondrial structure adaptations may provide an opportunity to overcome TNBC chemoresistance in the neoadjuvant setting. Citation Format: Lily Mokryun Baek, Junegoo Lee, James P. Barrish, Bora Lim, Jeffrey T. Chang, Phillip L. Lorenzi, Weston Porter, Gloria V. Echeverria. Morphological and functional plasticity of mitochondria in chemoresistant triple negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-01-08.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
丘比特的应助被shanguren采纳,获得10
刚刚
体贴寒烟完成签到,获得积分10
刚刚
Jennifer的应助被hzy采纳,获得20
刚刚
刚刚
木子完成签到,获得积分10
1秒前
灵巧谷波发布了新的文献求助10
1秒前
zhangyupei完成签到 ,获得积分10
2秒前
如初完成签到,获得积分10
2秒前
Roxrena完成签到 ,获得积分10
2秒前
byemaxf发布了新的文献求助10
2秒前
所所的应助被清欢采纳,获得10
2秒前
Piautos发布了新的文献求助10
2秒前
哈哈嘿发布了新的文献求助10
2秒前
夏春丽发布了新的文献求助10
3秒前
张璋完成签到,获得积分10
3秒前
youshiqiang完成签到,获得积分10
3秒前
liu发布了新的文献求助10
3秒前
Orange的应助被jolly0304采纳,获得10
3秒前
haung完成签到,获得积分10
3秒前
3秒前
深情安青的应助被xxtdger采纳,获得10
4秒前
molihuakai的应助被山东陈教授采纳,获得10
4秒前
lulu完成签到,获得积分10
4秒前
若木燃星发布了新的文献求助10
4秒前
4秒前
HUJL完成签到,获得积分10
4秒前
废纸箱发布了新的文献求助10
5秒前
动听千山发布了新的文献求助10
5秒前
5秒前
彭于彦祖的应助被唐璜采纳,获得30
5秒前
薯片完成签到,获得积分10
5秒前
萧离发布了新的文献求助10
6秒前
无花果的应助被生动晟睿采纳,获得10
6秒前
顾矜的应助被zhangyupei采纳,获得10
6秒前
quantumcell完成签到,获得积分10
7秒前
7秒前
可可萝oxo发布了新的文献求助10
8秒前
灵巧谷波完成签到,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8169283
求助须知:如何正确求助?哪些是违规求助? 9562312
关于积分的说明 21765402
捐赠科研通 7760880
什么是DOI,文献DOI怎么找? 3430267
关于科研通互助平台的介绍 2554102
邀请新用户注册赠送积分活动 2474953